The PPARγ2 Pro12Ala variant is protective against progression of nephropathy in people with type 2 diabetes. - Wikidata - wikimedia - TriplyDB

The PPARγ2 Pro12Ala variant is protective against progression of nephropathy in people with type 2 diabetes.

The PPARγ2 Pro12Ala variant is protective against progression of nephropathy in people with type 2 diabetes.

http://www.wikidata.org/entity/Q35174597

about

Nephroprotection by Hypoglycemic Agents: Do We Have Supporting Data?Network biology concepts in complex disease comorbidities Relationship between renal function and periodontal disease in community-dwelling elderly women with different genotypes.ISN Forefronts Symposium 2015: Nuclear Receptors and Diabetic Nephropathy Nitrolipids in kidney physiology and disease.

P2860

Q26777994-58334E01-63E8-4207-8C97-863F8A987411 Q29091067-1DE2A89C-D2AB-4093-BD92-22A5DAA16ECB Q40332415-5CBEDAAC-E014-4972-867D-D39B2CBCF093 Q41726958-77330F7D-3737-4333-B143-B6C03D091981 Q52722537-307C9544-C51E-4750-8E65-991DAEE1C147

P2860

The PPARγ2 Pro12Ala variant is protective against progression of nephropathy in people with type 2 diabetes.

http://www.wikidata.org/entity/Q35174597

description

2015 nî lūn-bûn

@nan

2015 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի մարտին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

The PPARγ2 Pro12Ala variant is ...... n people with type 2 diabetes.

@ast

The PPARγ2 Pro12Ala variant is ...... n people with type 2 diabetes.

@en

type

label

The PPARγ2 Pro12Ala variant is ...... n people with type 2 diabetes.

@ast

The PPARγ2 Pro12Ala variant is ...... n people with type 2 diabetes.

@en

prefLabel

The PPARγ2 Pro12Ala variant is ...... n people with type 2 diabetes.

@ast

The PPARγ2 Pro12Ala variant is ...... n people with type 2 diabetes.

@en

P1433

Q35174597-AD84ACC0-BB41-46E9-B670-2814FA58B3D0

P1476

Q35174597-E3B6D029-54D2-42D4-B672-0378717E4CE9

P2093

Q35174597-16950319-4AA7-45D6-B6D8-2BAEE294182A

Q35174597-3154A09F-EEC5-4811-BDF3-C8278BF998AE

Q35174597-659AA5F3-0805-487B-A9EE-1DBD7E283D9C

Q35174597-F5D94172-6C7B-476B-B448-34A18BB1E804

Q35174597-F864C713-63B7-44C9-AFD1-79FD19140073

P2860

Q35174597-1052017B-59E6-4F62-B38C-A951DE94124D

Q35174597-1B0EA2E3-C82F-43BA-B9B5-24AD7A829664

Q35174597-1C9E3A36-DFF4-4668-980A-5436B9A2A2CC

Q35174597-1E588184-E42F-4415-BDFF-6978E93ABB03

Q35174597-3E0C94C2-ADA9-4AC1-971B-92AEAD53D2C2

Q35174597-58FFC6C0-B988-4721-BF02-7D28E27BDFB5

Q35174597-662DAD73-AB87-47C7-BB34-91AA8A6EB1D0

Q35174597-696D2E97-95EA-419B-9A92-3F06487ADDB0

Q35174597-70DF084C-D826-4E1C-A1D5-516C71F45D60

Q35174597-80E653BF-36B5-4B06-A49A-46D041E4DC9C

P2888

Q35174597-164D65BE-B9B3-42DB-B7B5-88058B707307

P304

Q35174597-4CF77DE7-3B48-44A1-A6B2-3988D9388A36

P31

Q35174597-D5E996D1-8F77-4E4B-B26C-C877FEFDE25E

P356

Q35174597-FD395B21-22F1-4B0A-9836-FE8E85CF2907

P478

Q35174597-9A62EF6E-30FA-4673-B941-96ABC4DB09A0

P50

Q35174597-2E3E1E38-5A06-4191-97A1-0C719E348437

Q35174597-82F6CFC9-2DCA-459A-B4FB-E4309B2B31AE

Q35174597-A6F761D7-B451-47A2-8B21-B782790AAEA1

P577

Q35174597-38B82475-4449-431D-8C96-E51C81BD62E4

P5875

Q35174597-53AA8460-28E9-4566-9006-F3FBC009B5BC

P6179

Q35174597-6316A1CB-E42C-456F-AC44-D052C0B5C2B8

P698

Q35174597-CFDDCCF7-AFE5-4F15-B9C2-2E7D82FE849A

P921

Q35174597-0207D71B-BAE6-4B04-9D59-0D7E0A1470A5

P932

Q35174597-B87DA9A8-2816-4FE7-B3A0-BA51C71B9D56

P356

S12967-015-0448-6

P1433

Journal of Translational Medicine

P1476

The PPARγ2 Pro12Ala variant is ...... in people with type 2 diabetes

@en

P2093

Antonella Monticelli

http://www.w3.org/2001/XMLSchema#string

Emanuela Lapice

http://www.w3.org/2001/XMLSchema#string

Gabriele Riccardi

http://www.w3.org/2001/XMLSchema#string

Sara Cocozza

http://www.w3.org/2001/XMLSchema#string

Sergio Cocozza

http://www.w3.org/2001/XMLSchema#string

P2860

A new equation to estimate glomerular filtration rate

Pro12Ala polymorphism in the PPARG gene contributes to the development of diabetic nephropathy in Chinese type 2 diabetic patients.

The association between the peroxisome proliferator-activated receptor-gamma2 (PPARG2) Pro12Ala gene variant and type 2 diabetes mellitus: a HuGE review and meta-analysis.

Survival bias and drug interaction can attenuate cross-sectional case-control comparisons of genes with health outcomes. An example of the kinesin-like protein 6 (KIF6) Trp719Arg polymorphism and coronary heart disease.

Peroxisome proliferator-activated receptor γ polymorphism Pro12Ala Is associated with nephropathy in type 2 diabetes: evidence from meta-analysis of 18 studies

Protective effect of peroxisome proliferator activated receptor gamma agonists on diabetic and non-diabetic renal diseases.

Surrogate end points for clinical trials of kidney disease progression.

PPARγ signaling and metabolism: the good, the bad and the future.

Change in albuminuria and eGFR following insulin sensitization therapy versus insulin provision therapy in the BARI 2D study.

Impact of the PPAR-gamma2 Pro12Ala polymorphism and ACE inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: evidence from BENEDICT

P2888

s12967-015-0448-6

P304

85

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S12967-015-0448-6

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P50

Michele Pinelli

P577

2015-03-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

273701642

http://www.w3.org/2001/XMLSchema#string

P6179

1049685099

http://www.w3.org/2001/XMLSchema#string

P698

25889595

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

4358785

http://www.w3.org/2001/XMLSchema#string